Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$1.28 USD
+0.05 (4.07%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $1.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PACB 1.28 +0.05(4.07%)
Will PACB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PACB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PACB
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq
PACB: What are Zacks experts saying now?
Zacks Private Portfolio Services
PacBio Stock Up on Q2 Earnings & Revenue Beat Estimates, Margin Rises
Pacific Biosciences (PACB) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates
Other News for PACB
Sideways movement on September 17 results in no shift to PACB’s technical outlook
Technical picture remains unchanged for PACB after it rises 2.5% on September 16
Technical picture remains unchanged for PACB after it rises 2.56% on September 15
PACB falls 7.14% on September 12, leaving the technical picture intact
The technical outlook for PACB is unchanged after it rises 3.28% on September 11